Sandra Cuellar, PharmD, BCOP, discusses challenges with data extrapolation for biosimilars.
Sandra Cuellar, PharmD, BCOP
Advertisement
Articles by Sandra Cuellar, PharmD, BCOP
Sandra Cuellar, PharmD, BCOP, discusses the pharmacoeconomic benefits of biosimilars.
Advertisement
Latest Updated Articles
Dr. Cuellar on the Pharmacoeconomic Benefits of BiosimilarsApril 29th 2020
Dr. Cuellar on Concerns With Extrapolating Data for BiosimilarsAugust 19th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
FDA Awards Orphan Drug Designation to Enzomenib for ALL
4
Dr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer
5